Monograph: Deglycyrrhizinated licorice - Oral

Help on accessing alternative formats, such as Portable document format (PDF), Microsoft word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

This monograph is intended to serve as a guide to industry for the preparation of Product Licence Applications (PLA) and labels for natural health product market authorization. It is not intended to be a comprehensive review of the medicinal ingredient. It is a referenced document to be used as a labelling standard. Notes: Text in parentheses is additional optional information which can be included on PLA and on product label at the applicant's discretion. The solidus (/) indicates that the terms are synonyms or that the statements are synonymous. Either term or statement may be selected by the applicant.
Date: 2018-10-30

NHPID name

Deglycyrrhizinated licorice

Proper name(s)

Common name(s)

Deglycyrrhizinated licorice - Oral

Source material

Route Of administration

Oral

Dosage form(s)

The acceptable pharmaceutical dosage form for oral administration is limited to chewables (e.g. gummies, tablets).

Use(s) or purpose(s)

Statement(s) to the effect of:

Dose(s)

Duration of use

No statement is required

Risk information

Statement(s) to the effect of:

Caution(s) and Warning(s): Consult a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen. Contraindication(s): No statement is required Known Adverse Reaction(s): No statement is required

Non-medicinal ingredients

Must be chosen from the current Natural health products ingredients database and must meet the limitations outlined in the database.

Specifications

References cited

References reviewed

Appendix 1: Examples of appropriate dosage preparations, frequencies of use and directions for use

Oral:

380 mg DGL chewable tablets (1-4) between meals or 20 minutes before meals, 3 times per day (Murray and Pizzorno 2006)